HiFiBiO Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
237 Putnam Ave, Cambridge, Massachusetts...Website
www.hifibio.comRevenue
$22.7 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company was established in 2013 and is headquartered out of Cambridge, MA.Explore more
HiFiBiO Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is HiFiBiO Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when HiFiBiO Therapeutics launches new products
HiFiBiO Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if HiFiBiO Therapeutics is spiking on competitors!
Click to see if HiFiBiO Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if HiFiBiO Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on HiFiBiO Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once HiFiBiO Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at HiFiBiO Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to HiFiBiO Therapeutics
Compare insights from companies similar to HiFiBiO Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$132.7M
51-200
Public
$547.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
<$5M
11-50
Private
$11.2M
2010
JS
John SpringerSenior Director, Pharmaceutical Development Research & Development Project Management
Company Profile Activity
Activity Insights
HiFiBiO Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
HiFiBiO Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about HiFiBiO Therapeutics.
HiFiBiO Therapeutics financials insights
Gather financial insights about HiFiBiO Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series B
$37.5M
2019
Series C
$67M
2020
Debt
$350K
2021
Series D
$75M
HiFiBiO Therapeutics Tech Stack
A closer look at the technologies used by HiFiBiO Therapeutics
Most Recent Scoops
Person-Based
Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
, according to a high-level source in artificial intelligence, is planning to begin initiatives related to data labeling within three months. The organization will focus on labeling specific scientific data in support of these initiatives.
Data Management, Artificial Intelligence
Pain Point
Project
, according to a high-level source in artificial intelligence, is planning to remediate challenges related to conversational intelligence.
Pain Point, Business Intelligence, Customer Service, Language Technology, Customer Marketing, Artificial Intelligence, Language
Project
Machine Learning, Artificial Intelligence
HiFiBiO Therapeutics News & Media
Fierce Biotech Names HiFiBiO Therapeutics a “Fierce 15” Biotech Company of 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #biotech--HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, today announced that Fierce Biotech has named it as one of 2023’s “Fierce 15” biotechnology companies. The annual special report features the most innovative and promising early-stage biotechnology companies in the industry. “HiFiBiO Therapeutics is at the forefront of harnessing single-cell insights to bring innovative immunoHiFiBiO Therapeutics Announces First Patient Dosed with HFB200301 in Combination with tislelizumab in Patients with DIS® Selected Advanced Solid Tumors
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #HiFiBiO--HiFiBiO Therapeutics announces that the first patient has been dosed with HFB200301 in combination with tislelizumab for DIS® selected solid tumors.HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #DIS--HiFiBiO Therapeutics announces that the FDA has cleared the company's IND application for HFB200603, a novel anti-BTLA monoclonal antibody.HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #HFB200603--HiFiBiO announces clinical trial supply agreement to evaluate HFB200603 with tislelizumab in patients with DIS™ selected advanced solid tumors.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding HiFiBiO Therapeutics
Sign Up For FreeTo access detailed company insights
HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company was established in 2013 and is headquartered out of Cambridge, MA.... Read More
